Roivant Sciences Surges 15% After 'Transformational' Drug Data as $4.5 Billion Cash War Chest Fuels Biotech Ambitions
Roivant Sciences stock rockets 15% after reporting transformational Phase II results for brepocitinib in cutaneous sarcoidosis. With $4.5 billion in cash and an NDA filed for dermatomyositis, the biotech is on offense.